** Shares of biopharmaceutical company Legend Biotech LEGN.O slip 5.6% to $29.33 after at least two brokerages cut PT following Q1 results
** Truist cuts PT to $71 from $88; says co's multiple myeloma cancer drug Carvykti's U.S. growth was slower with manufacturing facility in partnership with Novartis AG NOVN.S needing time to ramp up
** "(LEGN has) the most efficacious cell therapy approved, and while there is a strong competitor in the clinic, the market is big enough to support multiple new modalities" - Truist
** RBC cuts PT to $78 from $84, retains "outperform" rating saying they see potential for supply to outstrip demand in 2026
** Co reports Q1 revenue of $195.1 mln and adj EPS loss of 7 cents vs analysts' estimates of $193.6 mln and adj. loss of 23 cents per share - LSEG data
** 22 out of 24 analysts rate stock as buy, two hold; median PT is $78
** Including session's move, LEGN down 9.7% YTD vs Nasdaq Biotechnology Index's .NBI decline of 7.9%
(Reporting by Twesha Dikshit)
((Twesha.Dikshit@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.